Literature DB >> 19858353

Mechanisms of exercise limitation and pulmonary rehabilitation for patients with neuromuscular disease.

L S Aboussouan1.   

Abstract

Indications for exercise and pulmonary rehabilitation extend to neuromuscular diseases tough these conditions pose particular challenges given the associated skeletal muscle impairment and respiratory muscle dysfunction. These challenges are compounded by the variety of exercise prescriptions (aerobic, muscle strengthening, and respiratory muscle training) and the variety of neuromuscular disorders (muscular, motor neuron, motor nerve root, and neuromuscular transmission disorders). Studies support a level II evidence of effectiveness (i.e., likely to be effective) for a combination of aerobic exercise and strengthening exercises in muscular disorders, and for strengthening exercises in amyotrophic lateral sclerosis. The potential deleterious effects of work overload in the dystrophinopathies have not been confirmed in Becker muscular dystrophy. Adjunctive pharmacologic interventions (e.g., theophylline, steroids, PDE5 inhibitors, creatine), training recommendations (e.g., interval or lower intensity training) and supportive techniques (e.g., noninvasive ventilation, neuromuscular electrical stimulation, and diaphragm pacing) may result in more effective training but require more study before formal recommendations can be made. The exercise prescription should include avoidance of inspiratory muscle training in hypercapnia or low vital capacity, and should match the desired outcome (e.g., extremity training for task-specific performance, exercise training to enhance exercise performance, respiratory muscle training where respiratory muscle involvement contributes to the impairment).

Entities:  

Mesh:

Year:  2009        PMID: 19858353     DOI: 10.1177/1479972309345927

Source DB:  PubMed          Journal:  Chron Respir Dis        ISSN: 1479-9723            Impact factor:   2.444


  8 in total

Review 1.  Exercise and amyotrophic lateral sclerosis.

Authors:  J P Lopes de Almeida; R Silvestre; A C Pinto; M de Carvalho
Journal:  Neurol Sci       Date:  2012-01-07       Impact factor: 3.307

Review 2.  Ventilatory control in ALS.

Authors:  Nicole L Nichols; J Van Dyke; L Nashold; I Satriotomo; M Suzuki; G S Mitchell
Journal:  Respir Physiol Neurobiol       Date:  2013-05-18       Impact factor: 1.931

3.  Long-term respiratory muscle endurance training in patients with myasthenia gravis: first results after four months of training.

Authors:  Beate Rassler; Grit Marx; Stephanie Hallebach; Petra Kalischewski; Irene Baumann
Journal:  Autoimmune Dis       Date:  2011-07-07

4.  Respiratory muscle training in children and adults with neuromuscular disease.

Authors:  Ivanizia S Silva; Rafaela Pedrosa; Ingrid G Azevedo; Anne-Marie Forbes; Guilherme Af Fregonezi; Mário Et Dourado Junior; Suzianne Rh Lima; Gardenia Mh Ferreira
Journal:  Cochrane Database Syst Rev       Date:  2019-09-05

5.  Inefficient skeletal muscle oxidative function flanks impaired motor neuron recruitment in Amyotrophic Lateral Sclerosis during exercise.

Authors:  F Lanfranconi; A Ferri; G Corna; R Bonazzi; C Lunetta; V Silani; N Riva; A Rigamonti; A Maggiani; C Ferrarese; L Tremolizzo
Journal:  Sci Rep       Date:  2017-06-07       Impact factor: 4.379

6.  Inspiratory muscle training in children and adolescents living with neuromuscular diseases: A pre-experimental study.

Authors:  Anri Human; Brenda M Morrow
Journal:  S Afr J Physiother       Date:  2021-08-31

Review 7.  Is there a role of pulmonary rehabilitation in extrapulmonary diseases frequently encountered in the practice of physical medicine and rehabilitation?

Authors:  Belma Füsun Köseoğlu
Journal:  Turk J Phys Med Rehabil       Date:  2022-06-01

8.  How do physical capacity, fatigue and performance differ in children with duchenne muscular dystrophy compared with their healthy peers?

Authors:  Akmer Mutlu; Halil Alkan; Tuzun Fırat; Aynur A Karaduman; Oznur T Yilmaz
Journal:  Neurosciences (Riyadh)       Date:  2018-01       Impact factor: 0.906

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.